ADCVCTAST
Non-randomized Single-center Study Phase II Evaluating the Efficacy and Toxicity of Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma
Sponsor study identifier
interventional
48
1 country
1
Study Start
June 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The purpose of this study is to achieving a six-month progression free survival (PFS) of patients receiving autologous dendritic cell vaccine (ADKV) loaded with allogeneic tumor lysate expression of cancer-testis antigens (CTA) in patients with soft tissue sarcomas
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2013
Date type not reportedThis date has not been verified as actual or estimated.
June 17, 2013
Actual (reported)June 21, 2013
Actual (reported)September 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
September 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Achieving a six-month progression free survival (PFS) of patients receiving ADKV with soft tissue sarcomas
Achieving a six-month time to progression (PFS) 40% of patients receiving ADKV loaded with allogeneic tumor lysate expressing PTA in patients with soft tissue sarcomas
6 month
Median progression-free survival
6 month
Median overall survival
6 month
Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
N. N. Petrov Research Institute of oncology
Saint Petersburg, 197758, Russia
Yuriy Komarov, PhD
N. N. Petrov Research Institute of oncology
First Submitted
June 17, 2013
First Posted
June 21, 2013
Study Start
June 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2020
Estimated (date passed)A Study of Olaratumab in Soft Tissue Sarcoma
Objective response rate
6 mounth
Assess biological response of tumors
6 mounth
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
November 20, 2019
Record last verified: 2019-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: